SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
Article content
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks.
Article content
SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4.
Article content
Article content
'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.'
Article content
'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.'
Article content
About SOLVE FSHD
Article content
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit https://www.solvefshd.com.
Article content
Article content
Article content
Article content
Contacts
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 hours ago
- CTV News
Asian shares climb after China and the U.S. say they have a framework for seeking a trade deal
TOKYO — Asian shares mostly rose Wednesday after China and the U.S. said they had agreed on a framework for following up on the trade truce reached last month in Geneva. U.S. futures fell while oil prices edged higher. Japan's benchmark Nikkei 225 surged 0.6% in afternoon trading to 38,450.76. Data from the Bank of Japan data showed wholesale inflation slowed in May, meaning there might be less pressure for the central bank to raise interest rates in its next policy board meeting. Hong Kong's Hang Seng gained 0.9% to 24,381.39, while the Shanghai Composite rose 0.5% to 3,402.97. Australia's S&P/ASX 200 edged up 0.2% to 8,603.70. South Korea's Kospi added 1.0% to 2,900.05. Tuesday on Wall Street, the S&P 500 rose 0.5% to 6,038.81 as the trade talks between the world's two largest economies carried into a second day. The Dow Jones Industrial Average added 0.2% to 42,866.87, and the Nasdaq composite gained 0.6% to 19,714.99. Stocks have roared higher since dropping roughly 20% below their record two months ago, when President Donald Trump shocked financial markets with his announcement of tariffs that were so stiff that they raised worries about a possible recession. Much of the rally has been due to hopes that Trump would lower his tariffs after reaching trade deals with countries around the world, and the S&P 500 is back within 1.7% of its record set in February. Analysts said that after two days of discussion in London, the late-night agreement reached appeared to be a consensus on what was already agreed upon before. Even so, Trump's approval is still needed. 'So what did 48 hours of talks actually produce? Apparently, a reaffirmation to eventually do what they had already said they would do. If markets were expecting substance, they got process instead,' said Stephen Innes, managing partner at SPI Asset Management. U.S. Secretary of Commerce Howard Lutnick said Tuesday evening in London that talks with China were going 'really, really well.' Both the United States and China have put many of their tariffs on each other's exports on pause as talks continue. Still, uncertainty over what is to come is still affecting companies and their ability to make profits. Designer Brands, the company behind the DSW shoe store chain, became the latest U.S. company to yank its financial forecasts for 2025 because of 'uncertainty stemming primarily from global trade policies.' The company, which also owns the Keds, Jessica Simpson and other shoe brands, reported a larger loss for the start of the year than analysts were expecting, and its revenue also fell short of forecasts. CEO Doug Howe pointed to 'persistent instability and pressure on consumer discretionary' spending, and the company's stock tumbled 18.2%. The uncertainty is moving in both directions, to be sure. A survey released Tuesday of optimism among small U.S. businesses improved a bit in May. 'While the economy will continue to stumble along until the major sources of uncertainty are resolved, owners reported more positive expectations on business conditions and sales growth,' according to Bill Dunkelberg, chief economist at the National Federation of Independent Business. Tesla helped to make up for such losses by rising 5.7%. The electric vehicle company has been recovering since tumbling last week as Elon Musk's relationship with Trump imploded. That raised fear about possible retaliation by the U.S. government against Tesla. Shares that trade in the United States of chipmaking giant Taiwan Semiconductor Manufacturing Co. rose 2.6% after the company known as TSMC said its revenue in May jumped nearly 40% from the year earlier. In other dealings early Wednesday, the yield on the 10-year Treasury eased to 4.48% from 4.47% late Tuesday. Benchmark U.S. crude oil gained 8 cents to US$65.06 a barrel. Brent crude, the international standard, edged up 2 cents to $66.89 a barrel. The U.S. dollar rose to 145.08 Japanese yen from 144.84 yen. The euro cost $1.1418, down from $1.1425. Yuri Kageyama, The Associated Press
National Post
11 hours ago
- National Post
Blue Planet Prize 2025: Announcement of Prize Laureates
Article content TOKYO — This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates. Article content 1. Professor Robert B. Jackson (USA) Born on September 26, 1961 Department of Earth System Science, Stanford University Article content Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions. Article content 2. Dr. Jeremy Leggett (UK) Born on March 16, 1954 Founder and CEO of Highlands Rewilding Ltd. Inaugural chairman of the Carbon Tracker Initiative Article content Dr. Jeremy Leggett, as the inaugural chairman of the Carbon Tracker Initiative (CTI), introduced the concept of the 'carbon bubble,' highlighting the economic risks associated with fossil fuel assets. Through CTI's activities, he influenced investors and policymakers, advancing the divestment movement. In addition, as a practical effort to balance economic activity with environmental conservation, he founded one of the UK's leading solar energy companies. More recently, he has been spearheading initiatives in Scotland to connect ecological restoration with community prosperity. Article content Each laureate is presented with a certificate of merit, a commemorative trophy, and 500,000 US dollars in prize money. The Award Ceremony is scheduled on Wednesday, October 29, 2025, at Tokyo Kaikan. Commemorative lectures will be given on October 30th and November 1st, 2025, at the University of Tokyo and at the Kyoto International Community House (kokoka), respectively. Article content Article content Article content Article content Article content Contacts Article content
CTV News
11 hours ago
- CTV News
Chinese shipyard chosen to build new BC Ferries
Vancouver Watch BC Ferries has chosen a Chinese state-run company to build four new vessels – a move that drew sharp criticism.
